Two Sigma Investments LP Has $978,000 Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

Two Sigma Investments LP reduced its stake in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 48.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,750 shares of the company's stock after selling 66,105 shares during the period. Two Sigma Investments LP owned 0.17% of SI-BONE worth $978,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of SI-BONE by 4.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company's stock valued at $328,000 after purchasing an additional 988 shares during the last quarter. Invesco Ltd. grew its stake in shares of SI-BONE by 8.9% in the fourth quarter. Invesco Ltd. now owns 17,203 shares of the company's stock valued at $241,000 after acquiring an additional 1,413 shares in the last quarter. Rhumbline Advisers lifted its position in SI-BONE by 3.0% during the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company's stock worth $808,000 after purchasing an additional 1,683 shares during the period. Barclays PLC lifted its position in SI-BONE by 2.7% during the fourth quarter. Barclays PLC now owns 99,212 shares of the company's stock worth $1,391,000 after purchasing an additional 2,589 shares during the period. Finally, Alliancebernstein L.P. lifted its position in SI-BONE by 6.2% during the fourth quarter. Alliancebernstein L.P. now owns 55,750 shares of the company's stock worth $782,000 after purchasing an additional 3,250 shares during the period. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on SIBN shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $24.00 price objective on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Truist Financial upped their price objective on shares of SI-BONE from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th.

SI-BONE Price Performance

Shares of SIBN stock traded down $0.16 on Friday, reaching $18.90. The company had a trading volume of 485,058 shares, compared to its average volume of 382,655. The stock has a market capitalization of $805.42 million, a PE ratio of -20.54 and a beta of 0.82. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $20.05. The business's 50-day moving average is $16.00 and its 200 day moving average is $15.47.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. The firm had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. Equities research analysts forecast that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

Insider Activity at SI-BONE

In related news, CFO Anshul Maheshwari sold 2,424 shares of the firm's stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $19.48, for a total value of $47,219.52. Following the completion of the transaction, the chief financial officer now owns 222,083 shares in the company, valued at $4,326,176.84. This trade represents a 1.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Laura Francis sold 38,504 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The shares were sold at an average price of $17.18, for a total transaction of $661,498.72. Following the completion of the transaction, the chief executive officer now owns 302,958 shares of the company's stock, valued at approximately $5,204,818.44. This trade represents a 11.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 92,565 shares of company stock worth $1,669,871 in the last quarter. 4.00% of the stock is owned by insiders.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.